Ameritas Advisory Services LLC Acquires New Holdings in Exelixis, Inc. $EXEL

Ameritas Advisory Services LLC acquired a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 34,270 shares of the biotechnology company’s stock, valued at approximately $1,502,000.

Other institutional investors also recently added to or reduced their stakes in the company. Farallon Capital Management LLC boosted its holdings in Exelixis by 21.6% in the third quarter. Farallon Capital Management LLC now owns 19,501,500 shares of the biotechnology company’s stock worth $805,412,000 after acquiring an additional 3,466,000 shares in the last quarter. Assetmark Inc. boosted its holdings in Exelixis by 1,230.8% in the third quarter. Assetmark Inc. now owns 3,195,971 shares of the biotechnology company’s stock worth $131,994,000 after acquiring an additional 2,955,813 shares in the last quarter. AQR Capital Management LLC boosted its holdings in Exelixis by 20.7% in the third quarter. AQR Capital Management LLC now owns 9,181,359 shares of the biotechnology company’s stock worth $379,190,000 after acquiring an additional 1,575,280 shares in the last quarter. Allianz Asset Management GmbH boosted its holdings in Exelixis by 153.3% in the third quarter. Allianz Asset Management GmbH now owns 2,462,948 shares of the biotechnology company’s stock worth $101,720,000 after acquiring an additional 1,490,520 shares in the last quarter. Finally, UBS Group AG boosted its holdings in Exelixis by 100.1% in the third quarter. UBS Group AG now owns 2,655,069 shares of the biotechnology company’s stock worth $109,654,000 after acquiring an additional 1,328,087 shares in the last quarter. Institutional investors own 85.27% of the company’s stock.

Exelixis Price Performance

Exelixis stock opened at $51.10 on Friday. The stock has a market capitalization of $12.84 billion, a PE ratio of 16.98, a price-to-earnings-growth ratio of 1.08 and a beta of 0.38. Exelixis, Inc. has a 12 month low of $33.76 and a 12 month high of $51.63. The business has a 50 day simple moving average of $44.13 and a 200-day simple moving average of $43.44.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.75 by $0.12. The business had revenue of $610.81 million during the quarter, compared to analysts’ expectations of $607.51 million. Exelixis had a return on equity of 39.89% and a net margin of 35.08%.The business’s revenue was up 10.0% compared to the same quarter last year. During the same period in the previous year, the business earned $0.55 earnings per share. On average, equities research analysts anticipate that Exelixis, Inc. will post 3.15 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on EXEL. Morgan Stanley lifted their target price on Exelixis from $49.00 to $50.00 and gave the stock an “equal weight” rating in a report on Wednesday, May 6th. Royal Bank Of Canada decreased their target price on Exelixis from $46.00 to $43.00 and set a “sector perform” rating for the company in a report on Monday, March 2nd. Truist Financial raised Exelixis to a “strong-buy” rating in a report on Monday, April 27th. TD Cowen lifted their target price on Exelixis from $51.00 to $55.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Finally, Wall Street Zen raised Exelixis from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eleven have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $47.35.

Insider Transactions at Exelixis

In other news, Director Jack L. Wyszomierski sold 99,574 shares of Exelixis stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $44.01, for a total value of $4,382,251.74. Following the sale, the director directly owned 279,942 shares of the company’s stock, valued at $12,320,247.42. The trade was a 26.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Maria C. Freire sold 20,634 shares of Exelixis stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $46.00, for a total value of $949,164.00. Following the completion of the sale, the director directly owned 100,819 shares in the company, valued at $4,637,674. This represents a 16.99% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 382,811 shares of company stock valued at $17,014,813. Insiders own 2.60% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.